We evaluated the effects of angiotensin-converting enzyme (ACE) inhibition on metabolic changes in myocardial organelles, myocardial hypertrophy, and interstitial fibrosis in the early stage of hypertension. An ACE inhibitor, imidapril (2.5mg/kg per day), a calcium-channel blocker, diltiazem (30mg/kg per day), or vehicle was given to spontaneously hypertensive rats (SHRs) from 10 to 18 weeks of age. Single myocytes were isolated enzymatically from the left ventricles of these SHRs and normotensive Wistar-Kyoto (WKY) controls at 18 weeks of age. In single ventricular myocytes, enzyme activities in the sarcoplasmic reticulum (SR) and the sarcolemma (SL) and the mitochondrial respiratory control ratio (RCR) were determined. In 18-week-old SHRs receiving vehicle, myocardial hypertrophy and interstitial fibrosis developed, and SR Ca2+ ATPase activity and the mitochondrial RCR were significantly lower and SL Na+, K+-ATPase activity was significantly higher than in age-matched WKYs. However, compared with diltiazem, imidapril was better able to prevent the development of myocardial hypertrophy and interstitial fibrosis, to improve SR Ca2+-ATPase activity and the mitochondrial RCR, and to increase SL Na+, K+-ATPase activity. These results suggest that ACE inhibition can prevent the development of morphologic changes associated with hypertension-induced left ventricular remodeling, such as myocardial hypertrophy and interstitial fibrosis, and can counteract ongoing dysfunction of organelle metabolism early in the development of hypertension. (Jpn Heart J 1997; 38: 503-514) 
sion has been considered from the viewpoint of long-term prognosis.2,3) Although numerous antihypertensive drugs are now available, calcium-channel blockers and angiotensin-converting enzyme (ACE) inhibitors are most widely used. Calcium-channel blockers were initially developed for treatment of ischemic heart disease and also are now used for control of hypertension.4) ACE inhibitors have been the subject of numerous studies in both animals5,6) and humans. 7, 8) In addition to having antihypertensive effects, ACE inhibitors reverse structural changes in myocardium associated with remodeling.9-11) Although these beneficial effects of ACE inhibitors have been studied extensively, little is known about the effects on metabolic changes in myocardial organelles.
In this study, we used single myocytes isolated from the left ventricle of spontaneously hypertensive rats (SHRs), which are widely regarded as the best animal model of human genetic hypertension, to exclude any neuronal or hormonal influences and investigated structural and metabolic changes in myocardial organelles early in the development of hypertension. We also evaluated the cardioreparative effect of ACE inhibitors on these changes and their antihypertensive effect compared with those of calcium-channel blockers in single left ventricular myocytes of SHRs.
MATERIALS AND METHODS

Animal experiment:
Forty 10-week-old male SHRs were used in this study. At this age, hypertension is regarded to be at an early stage of development. Twenty 10-week-old male normotensive Wistar-Kyoto rats (WKYs) served as controls. First, 10 SHRs and 10 WKYs were sacrificed at 10 weeks of age to investigate hypertension-induced left venticular remodeling and metabolic changes in myocardial organelles. The remaining 30 SHRs were randomly divided into three groups of 10 animals, which received imidapril, an ACE inhibitor, 2.5mg/kg per day; diltiazem, a calcium-channel blocker, 30mg/kg per day; or vehicle only. The remaining 10 WKYs received the same vehicle. Drugs and vehicle were administered orally via a stomach tube daily from 10 weeks of age for 8 weeks. The three groups of SHRs and the WKYs were sacrified at 18 weeks of age to evaluate the effects of the drugs on left ventricular remodeling and metabolic changes in myocardial organelles. Blood pressure was measured in all animals at 10 and 18 weeks of age with the standard tail-cuff method. Isolation of single ventricular myocytes: Left ventricular myocytes were obtained by enzymatic digestion of hearts according to the method of Tytgat.12) Rats were anesthetized with sodium pentobarbital (70mg/kg, i.p.) and kept in the supine position for about 10 minutes. Blood was obtained from the abdominal aorta to measure plasma renin activity and angiotensin II. mesh to eliminate large superfluous cellular material and washed twice with the basic solution supplemented with 1.0% BSA. The yield was determined by cell count, and cells were considered viable when they appeared rod-shaped on light microscopy. This method routinely produced 70% to 80% fresh, rod-shaped cells. Aliquots of the isolated-cell suspension were treated with saponin (Sigma, St. Louis, MO) for 2 minutes to produce permeabilized ventricular myocytes.13) After the cells had settled, the supernatant was gently discarded with a pipette to wash out saponin and replaced with a cytosolic solution containing 20mM NaCl, 100mM KCl, 5MM MgSO4, 0.96mM NaH2PO4, 1mM EGTA, 5mM HEPES, and 1.0% BSA at pH 7.2 and room temperature. Biochemical analysis: The Ca2+-ATPase activity of the sarcoplasmic reticulum (SR), the Ca2+-ATPase activity and the Na+, K+-ATPase activity of the sarcolemma (SL), and the respiratory activity of mitochondria were determined with permeabilized ventricular myocytes in the absence of neuronal or hormonal influences.
The SR Ca2+-ATPase activity was measured according to the modified microtome (Sorvall MT-2, Dupont, USA). Sections were double-stained and observed with an electron microscope (Hitachi H-300, Tokyo, Japan).
the data was performed using Student's t-test for unpaired observations. When more than two groups were compared, ANOVA was used. Differences were considered statistically significant at p<0.05.
RESULTS
Body weight and heart weight: Body weight and heart weight were significantly lower in untreated SHRs than in WKYs (both p<0.05) at 10 weeks of age (Table II) . Further- more, myocardial transverse diameter and areas occupied by interstitial fibrosis were significantly greater (both p<0.001) in vehicle-treated SHRs than in WKYs at 18 weeks of age. However, myocardial transverse diameter (p<0.01) and areas occupied by interstistial fibrosis (p<0.001) were significantly lower in imidapril-treated SHRs than in vehicle-treated SHRs but did not differ significantly between diltiazem-treated SHRs and vehicle-treated SHRs. On ultrastructural observation of myocardium, differences between untreated SHRs and WKYs did not differ markedly at 10 weeks of age. However, several mitochondria were slightly swollen and some cristae were disrupted only in vehicle-treated SHRs at 18 weeks of age (Figure 1 ). Only imidapril tended to decrease these changes in myocardial organelles. SR Ca2+-ATPase activity: The SR Ca2+-ATPase activity was significantly lower Pi/cell/hour, p<0.01) at 18 weeks of age. However, the activity was significantly hicle-treated SHRs but did not differ significantly between imidapril-treated SHRs and diltiazem-treated SHRs.
SL Ca2+-ATPase activity:
The SL Ca2+-ATPase activity did not differ between age ( Figure 3 ). The SL Ca2+-ATPase activity improved significantly more only in treated SHRs but did not differ significantly between diltiazem-treated SHRs SL Na+, K+-ATPase activity:
The SL Na+, K+-ATPase activity was significantly Blood pressure is significantly higher in SHRs than WKYs at 5 weeks of age and increases further only in SHRs by about 5 to 10 weeks of age.21) We investigated metabolic changes in organelles of the SHR heart at 10 weeks, when hypertension is regarded to be at an early stage of development. We found that mitochondrial respiratory activity and SL Ca2+-ATPase activity were maintained at 10 weeks, that SR Ca2+-ATPase activity had significantly decreased, and that SL Na+, K+-ATPase activity had significantly increased. Left ventricular hypertrophy and the metabolic changes in organelles of the SHR heart stated above were observed early in the development of hypertension and then tended to progress with age. The heart weight and the heart-to-body weight ratio could be reduced and the depressed activity of SR Ca2+-ATPase associated with pressure overload could be reversed by administration of an ACE inhibitor, imidapril, and a calcium-channel blocker, diltiazem. The reversal of hypertension-induced cardiac hypertrophy and dysfunction of SR Ca2+-ATPase activity may be related to the antihypertensive effects of both drugs. Diltiazem has the beneficial effects of preventing left ventricular hypertrophy, preserving left ventricular function,31) and protecting SR Ca2+-ATPase activity against ischemic injury.32) Imidapril significantly reduced plasma levels of angiotensin II and prevented the development of myocardial hypertrophy and interstitial fibrosis. In contrast, the effects of diltiazem were not significant. ACE inhibitors can decrease volume overload by inhibiting the renin-angiotensin system and, by inhibiting the local production of angiotensin II in the heart, can suppress the development of myocardial hypertrophy and interstitial fibrosis.33,34) The recently introduced angiotensin II receptor antagonists, losartan and TCV-116, can provide similar benefits.35,36) Blockade of the renin-angiotensin system is thought to be important in the prevention of the development of left ventricular remodeling as well as in the prevention of hypertension. In this study, imidapril restored the activities of SL Ca2+-ATPase and mitochondrial respiration significantly more than did diltiazem. Imidapril had greater beneficial effects on hypertension-induced myocardial hypertrophy, interstitial fibrosis, and metabolic dysfunction of myocardial organelles than did diltiazem despite a lack of difference in antihypertensive effect.37) ACE inhibitors might be more beneficial than calcium-channel blockers for reversing hypertension-induced structural and metabolic changes in myocardium.
Diltiazem normalized SL Na+-K+ ATPase activity of SHRs to that of WKY controls. In contrast, imidapril significantly increased SL Na+, K+-ATPase activity, thereby altering the ionic environment of myocytes. However, whether an increase in SL Na+, K+-ATPase activity induced by ACE inhibition benefits the heart is still controversial. Our hypothesis for the mechanism by which SL Na+, K+-ATPase activity is increased is described below. Inhibition of ACE suppresses not only the production of angiotensin II but also the breakdown of bradykinin. 38, 39) In the heart, local bradykinin might activate the Na+, H+ exchange system40) and, consequently, Na+ might be incorporated in the myocyte. The Na+, K+ ATPase activity might then be increased to compensate for the increase in intracellular Na+.
Conclusion:
Inhibition of ACE could prevent the development of morphologic Vol 38 No 4 CARDIOREPARATIVE EFFECTS OF ACE INHIBITION 513 changes associated with hypertension-induced left ventricular remodeling, such as myocardial hypertrophy and interstitial fibrosis, and could reverse ongoing dysfunction of organelle metabolism early in the development of hypertension.
